Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Share-based Compensation (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Share-based Compensation for 8 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 25.41% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.7 million, a 2.39% decrease, with the full-year FY2024 number at $12.6 million, down 10.23% from a year prior.
  • Share-based Compensation was $2.4 million for Q3 2025 at Precision Biosciences, down from $2.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.1 million in Q2 2022 to a low of $2.4 million in Q3 2025.
  • A 5-year average of $3.7 million and a median of $3.6 million in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 31.88% in 2022, then plummeted 39.51% in 2023.
  • Precision Biosciences' Share-based Compensation stood at $4.4 million in 2021, then rose by 2.28% to $4.5 million in 2022, then crashed by 34.55% to $3.0 million in 2023, then rose by 20.28% to $3.6 million in 2024, then plummeted by 33.18% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Share-based Compensation are $2.4 million (Q3 2025), $2.9 million (Q2 2025), and $2.8 million (Q1 2025).